文献速递妇科产科

机会性输卵管切除术对卵巢癌死亡率与医疗费用的影响:呼吁全民保险覆盖

The impact of opportunistic salpingectomy on ovarian cancer mortality and healthcare costs: a call for universal insurance coverage.
PubMed 文献 · Am J Obstet Gynecol · 2021-03-31

本研究构建覆盖8个州的马尔可夫状态转移模型,评估在输卵管结扎或子宫切除术时行机会性输卵管切除术对卵巢癌死亡率与总体费用的影响。作者据此呼吁第三方支付方将机会性输卵管切除术纳入保险覆盖。

要点

  • 结扎时机会性输卵管切除术预计降低卵巢癌死亡率8.13%,子宫切除时降低6.34%,合计14.5%。
  • 两种策略均具成本效果,结扎时增量成本效果比为每生命年6401美元、每质量调整生命年5469美元。
  • 全民机会性输卵管切除术预计每年预防1854例卵巢癌死亡并降低医疗费用。

核心结论

  • 机会性输卵管切除术在输卵管结扎和子宫切除时实施可降低卵巢癌死亡率并节省医疗费用,应纳入第三方支付方保险覆盖。

研究设计与样本

  • 构建8个州马尔可夫状态转移模型,涵盖子宫切除、输卵管结扎与卵巢癌,转移概率来自既往人群数据并含年龄调整的择期绝育与子宫切除率。
  • 模型自20岁运行至85岁,以1年为间隔并采用半步校正,纳入年龄调整的输卵管结扎、子宫切除(含与不含卵巢切除)及卵巢癌发生率。
  • 模型测试显示其可准确预测总体预期寿命并较好预测人群子宫切除率,但可能低估输卵管绝育率,因而对输卵管切除术获益偏保守。

主要发现

  • 结扎时机会性输卵管切除术预计降低卵巢癌死亡率8.13%,子宫切除时降低6.34%,合计降低14.5%。
  • 仅计机会性输卵管切除术成本时两种策略均具成本效果。
  • 结扎时机会性输卵管切除术的超额成本为433.91美元,增量成本效果比为每生命年6401美元、每质量调整生命年5469美元(卵巢癌效用值0.64)。
  • 子宫切除时机会性输卵管切除术成本为124.70美元,增量成本效果比为每生命年2006美元、每质量调整生命年1667美元。

关键数值与推荐

  • 结扎时机会性输卵管切除术:死亡率降低8.13%,超额成本433.91美元,每生命年6401美元,每质量调整生命年5469美元。
  • 子宫切除时机会性输卵管切除术:死亡率降低6.34%,成本124.70美元,每生命年2006美元,每质量调整生命年1667美元。

临床怎么用

  • 在输卵管结扎或子宫切除时可考虑同时行机会性输卵管切除术以降低卵巢癌死亡率。
  • 应向支付方倡导将机会性输卵管切除术纳入保险覆盖,以消除 adoption 的经济障碍。
  • 咨询时可告知患者该策略具成本效果并可能带来医疗费用节省。

局限性

  • 模型基于既往人群数据与假设,可能低估输卵管绝育率,对获益估计偏保守。
  • 成本效果结果依赖模型参数与效用值假设,敏感性分析仅围绕输卵管切除术获益进行。
  • 结果为模型预测而非前瞻性临床研究验证,外推至其他人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Opportunistic salpingectomy at the time of hysterectomy or as an alternative to bilateral tubal ligation may reduce the incidence of ovarian cancer, because it has been demonstrated that most serous ovarian cancers begin in the fallopian tubes. However, salpingectomy at the time of sterilization is not always financially covered by third-party payers, and this represents a barrier to adoption. Routine salpingectomy has become more common but is not always practiced at the time of hysterectomy. OBJECTIVE: This study aimed to determine the impact of opportunistic salpingectomy as an alternative tubal ligation and routine salpingectomy at the time of hysterectomy on ovarian cancer mortality and overall cost. STUDY DESIGN: An 8-state Markov state transition model was constructed, including hysterectomy, tubal ligation, and ovarian cancer. Transition probabilities were informed by previously reported population data and include age-adjusted rates of elective sterilization and hysterectomy. This model was used to predict ovarian cancer incidence and the cost effectiveness of opportunistic salpingectomy. Testing of this model suggested that it accurately predicted overall life expectancy and closely predicted the rate of hysterectomy in the population. The model may underestimate the rate of tubal sterilization, making it conservative with respect to the benefits of salpingectomy. RESULTS: The recursive Markov model was run from ages 20 to 85 years in 1-year intervals with a half step correction and included age-adjusted rates of tubal ligation, hysterectomy (with and without oophorectomy), and ovarian cancer. The model predicts that opportunistic salpingectomy at the time of tubal ligation will reduce ovarian cancer mortality by 8.13%. Opportunistic salpingectomy at the time of hysterectomy will reduce ovarian cancer mortality by 6.34% for a combined decrease of 14.5%. Both strategies are cost effective when considering only the cost of the opportunistic salpingectomy. The excess cost of opportunistic salpingectomy at the time of tubal ligation was $433.91 with an incremental cost-effective ratio of $6401 per life-year and $5469 per quality-adjusted life year gained when adjusting for ovarian cancer with a utility of 0.64. The incremental cost-effective ratio for opportunistic salpingectomy during hysterectomy at a cost of $124.70 was $2006 per life-year and $1667 per quality-adjusted life year. When considering the impact of ovarian cancer prevention with respect to the cost of ovarian cancer treatment, opportunistic salpingectomy may produce a substantial healthcare savings. Utilizing a 3% discount rate, it is estimated that the total savings for universal salpingectomy could be as high as $445 million annually in the United States. A sensitivity analysis around the benefit of opportunistic salpingectomy suggests that this procedure will be cost effective even if salpingectomy provides only a modest reduction in the risk of ovarian cancer. CONCLUSION: It is estimated that universal opportunistic salpingectomy may prevent 1854 deaths per year from ovarian cancer and may reduce healthcare costs. Given these data, universal opportunistic salpingectomy should be considered at the time of tubal ligation and hysterectomy and covered by third-party payers.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Naumann RW, Hughes BN, Brown J, et al. The impact of opportunistic salpingectomy on ovarian cancer mortality and healthcare costs: a call for universal insurance coverage. Am J Obstet Gynecol. 2021. PMID: 33798477. doi:10.1016/j.ajog.2021.03.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。